Dexamfetamine

Central Nervous System Stimulant — NERVOUS SYSTEM

Key facts

Dexamfetamine is an ofp drug in the Central Nervous System Stimulant class catalogued in DrugCentral. It was first approved by the FDA in 1955. DrugCentral lists 17 molecular targets, including Taar1, Taar1 and SLC6A2. Recorded indications include Attention deficit hyperactivity disorder and Narcolepsy.

• Approval status: ofp (first approved 1955 by the FDA).
• Drug class: Central Nervous System Stimulant.
• Molecular targets: Taar1, Taar1, SLC6A2 and TAAR1 (17 listed in DrugCentral).
• Indications: Attention deficit hyperactivity disorder and Narcolepsy.
• ATC code: N06BA02 (Centrally acting sympathomimetics).
• Molecular formula: C9H13N; molecular weight 135.21 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Attention deficit hyperactivity disorder
• Narcolepsy

Contraindications (29)

• Aggressive behavior
• Anorexia nervosa
• Arteriosclerotic vascular disease
• Bipolar disorder
• Breastfeeding (mother)
• Cardiomyopathy
• Cardiovascular event risk
• Cerebrovascular accident
• Chronic heart failure
• Conduction disorder of the heart
• Dependent drug abuse
• Disorder of cardiovascular system
• Disorder of coronary artery
• Feeling agitated
• Gilles de la Tourette's syndrome
• Glaucoma
• Hypertensive disorder
• Hypertensive urgency
• Hyperthyroidism
• Mania
• Motor tic disorder
• Myocardial infarction
• Myocardial infarction in recovery phase
• Psychotic disorder
• Seizure disorder
• Structural disorder of heart
• Substance abuse
• Visual impairment
• Weight loss

Mechanism & targets

• Established pharmacologic class: Central Nervous System Stimulant

Molecular targets (17)

Target	Gene	Action	Activity
Trace amine-associated receptor 1	Taar1	unknown	EC50 8.70
Trace amine-associated receptor 1	Taar1	unknown	EC50 7.25
Sodium-dependent noradrenaline transporter	SLC6A2	inhibitor	Ki 7.00
Trace amine-associated receptor 1	TAAR1	unknown	EC50 6.87
Sodium-dependent dopamine transporter	SLC6A3	releasing agent	Ki 6.68
Trace amine-associated receptor 1	TAAR1	unknown	EC50 6.00
Sodium-dependent serotonin transporter	Slc6a4	unknown	EC50 5.75
Serotonin (5-HT) receptor	Htr2c|Htr2a|Htr1a|Htr1b|Htr1d|Htr1f|Htr2b|Htr6|Htr7|Htr5a|Htr5b|Htr3a|Htr4|Htr3b	unknown	Kd 5.35
Sodium-dependent dopamine transporter	Slc6a3	unknown	IC50 5.31
Sodium-dependent serotonin transporter	SLC6A4	unknown	Ki 5.24
5-hydroxytryptamine receptor 1A	HTR1A	unknown	Ki 5.18
Amine oxidase [flavin-containing] A	Maoa	unknown	Ki 4.91
Amine oxidase [flavin-containing] A	MAOA	unknown	Ki 4.84
Cocaine- and amphetamine-regulated transcript protein	CARTPT	unknown	—
Alpha-2A adrenergic receptor	ADRA2A	unknown	—
Alpha-1A adrenergic receptor	ADRA1A	unknown	—
Synaptic vesicular amine transporter	SLC18A2	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1955-09-09	FDA	—	UCB INC

ATC classification

ATC code	Therapeutic hierarchy
N06BA02	NERVOUS SYSTEM › PSYCHOANALEPTICS › PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS › Centrally acting sympathomimetics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Application site erythema	178.8
Suicidal ideation	166.6
Product administration interrupted	164.6
Application site pain	161.7
Anxiety	160.7
Application site irritation	148.9
Oppositional defiant disorder	134.0
Depression	119.8
Decreased eye contact	119.6
Aggression	114.5
Bruxism	103.9
Product substitution issue	100.0

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Dexamfetamine is on its molecule page.

• Molecular formula: C₉H₁₃N
• Molecular weight: 135.21 g/mol
• CAS number: 51-64-9
• InChIKey: KWTSXDURSIMDCE-QMMMGPOBSA-N
• PubChem CID: 5826

C[C@H](N)CC1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dexamfetamine used for?

DrugCentral lists the following indications for Dexamfetamine: Attention deficit hyperactivity disorder and Narcolepsy.

How does Dexamfetamine work?

Its molecular targets in DrugCentral include Taar1, Taar1, SLC6A2 (inhibitor) and TAAR1.

When was Dexamfetamine first approved?

Dexamfetamine was first approved by the FDA in 1955.

What drug class does Dexamfetamine belong to?

Dexamfetamine is in the Central Nervous System Stimulant class.

What is the chemical formula of Dexamfetamine?

Dexamfetamine has the molecular formula C9H13N and a molecular weight of 135.21 g/mol.

Sources

• DrugCentral drug card 841 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200782 — compound record and bioactivity
• PubChem CID 5826 — chemical identifiers
• DrugBank DB01576 — drug record
• FDA UNII TZ47U051FI — substance identity
• DailyMed: FDA labels for Dexamfetamine — current prescribing information (label search)
• UniProt P23975 (SLC6A2) — target protein
• UniProt Q96RJ0 (TAAR1) — target protein
• UniProt Q01959 (SLC6A3) — target protein
• UniProt P31645 (SLC6A4) — target protein
• UniProt P08908 (HTR1A) — target protein
• UniProt P21397 (MAOA) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.